Ra Capital Management, L.p. bought $424M of PBLS
director, owner at Parabilis Medicines, Inc.. 21,188,750 shares at an average of $20.00, traded Jun 11, 2026, filed Jun 15, 2026.
Score components
- +15RoleDirector
- +25Trade size$423.8M at market
- +10Relative to holdingsHoldings up 323%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -16% over 21 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000638, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | CConversion Voting Common Stockindirect: See footnotes | +6,556,740 | - | - | 6,556,740 | Jun 15, 2026 |
| Jun 11, 2026 | CConversion Voting Common Stockindirect: See footnotes | +1,187,881 | - | - | 1,187,881 | Jun 15, 2026 |
| Jun 11, 2026 | POpen-market purchase Voting Common Stockindirect: See footnotes | +19,728,353 | $20.00 | $395M | 26,285,093 | Jun 15, 2026 |
| Jun 11, 2026 | POpen-market purchase Voting Common Stockindirect: See footnotes | +1,460,397 | $20.00 | $29M | 2,648,278 | Jun 15, 2026 |
| Jun 11, 2026 | CConversion Series E Preferred Stockderivativeindirect: See footnotes | -642,250 | - | - | 0 | Jun 15, 2026 |
| Jun 11, 2026 | CConversion Series E Preferred Stockderivativeindirect: See footnotes | -160,562 | - | - | 0 | Jun 15, 2026 |
| Jun 11, 2026 | CConversion Series F Preferred Stockderivativeindirect: See footnotes | -9,445,363 | - | - | 0 | Jun 15, 2026 |
| Jun 11, 2026 | CConversion Series F Preferred Stockderivativeindirect: See footnotes | -1,666,829 | - | - | 0 | Jun 15, 2026 |
Related signals
Other insiders at Parabilis Medicines, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | PBLSbuy Parabilis Medicines, Inc. | Ra Capital Management, L.p. director, owner | $6.9M 244,593 shares | +1% | |
| 57Moderate | Parabilis Medicines, Inc. | Guy Levy owner | $10M 500,000 shares | +77% | |
| 62Notable | Parabilis Medicines, Inc. | Alan Sebulsky director | $474k 17,500 shares | +140% | |
| 51Moderate | Parabilis Medicines, Inc. | Alan Sebulsky director | $250k 12,500 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.